about
Two-step synthesis of achiral dispiro-1,2,4,5-tetraoxanes with outstanding antimalarial activity, low toxicity, and high-stability profiles.Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins.A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.Identification of novel antimalarial chemotypes via chemoinformatic compound selection methods for a high-throughput screening program against the novel malarial target, PfNDH2: increasing hit rate via virtual screening methods.Antimalarial pharmacology and therapeutics of atovaquoneIdentification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malariaRational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis.Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.Targeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era.Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000-compound diversity library.Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.Endoperoxide carbonyl falcipain 2/3 inhibitor hybrids: toward combination chemotherapy of malaria through a single chemical entity.Development of a novel drug for uncomplicated malaria targeting the mitochondrial NADH:quinone oxidoreductase.A novel drug for uncomplicated malaria: targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNdh2) of Plasmodium falciparum.Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease.
P50
Q33323905-F107D641-BA04-41CD-96AB-D7EE8C6FAABBQ33632425-0B4BD39F-23D0-4C23-8BD0-4025EDC09FDFQ33761137-0257F57C-4367-4EDD-9BA4-1BFB34E1C222Q34180451-6956D3D5-236E-4DC8-B816-550957132520Q35131253-65030649-ADAF-470C-832C-95E5AB714397Q35814421-0880DB8F-0E7F-4281-8F37-C9DD052C15A2Q35958086-0A007A4B-EFB1-4AD7-8534-4C93CDCB2358Q35991425-4F6B4F31-6557-46A0-BDCB-DC9C70057458Q36311780-F7346C92-5C87-424A-B911-D4133CE4B14BQ38704757-7EC0EB4C-1E03-4AF8-BDD1-6143A7168E81Q39231995-92162F18-D1F1-45C6-8985-2AFF46C5EA1EQ39306287-B761CD6D-1DAB-48F8-972C-205EE1E746B5Q41678406-3C9D7E12-EEED-424A-BA28-408C9272B0E7Q41938916-64D8CDC5-9638-47E3-9959-2B1F57D606D6Q42846251-31B764C4-8677-443A-A4F3-823D007DC76DQ45973147-7658DC74-84EA-43B9-9866-AE02A43E6FD6Q45973562-EE458B47-4875-4615-966B-43B7E955D76DQ47561431-AF96097B-F9C2-4C66-84DA-3109F2B9CA43
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gemma Nixon
@ast
Gemma Nixon
@en
Gemma Nixon
@es
Gemma Nixon
@nl
Gemma Nixon
@sl
type
label
Gemma Nixon
@ast
Gemma Nixon
@en
Gemma Nixon
@es
Gemma Nixon
@nl
Gemma Nixon
@sl
altLabel
Gemma L Ellis
@en
prefLabel
Gemma Nixon
@ast
Gemma Nixon
@en
Gemma Nixon
@es
Gemma Nixon
@nl
Gemma Nixon
@sl
P106
P21
P31
P496
0000-0002-9730-0960